RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals December 16, 2022 - "PwC stated that since pharma and life sciences brands have “ample corporate cash” on hand, there is an expectation that companies will make investments to address medium-term pipeline gaps and reset biotech valuations that ballooned last year.
The report also stated that since the midterm election results are decided and aspects of the Inflation Reduction Act are better known, companies should face less uncertainty in 2023 compared to 2022.
“We expect to see activity in areas of high expected future growth in 2023,” the report stated. “Pharma and biotech M&A will continue to focus on oncology and immunology, but other areas such as central nervous system and cardiovascular diseases as well as vaccines will see interest. We expect that the market will place a significant premium on therapeutic area leadership.”
Looking at industry subsectors, PwC projected that pharma and biotech M&A activity will continue to focus on the oncology and immunology spaces."
https://www.mmm-online.com/home/channel/pwc-optimistic-for-pharma-ma-in-2023-despite-economic-headwinds/
https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html